01
Democratization of In-Vitro Diagnostics
Making diagnostics more accessible, affordable, and scalable across clinical and at-home settings.
The First Bio-Fabless Diagnostics Company
Where Silicon Meets
Biology
Clinical answers at semiconductor speed. Our BioFET platform delivers results in minutes — not days — across infectious disease, neurodegeneration, and oncology.
Pioneering the Next Generation of Diagnostics Platform Built on
Semiconductor Sensors
Novascope Biochips is committed to democratizing in-vitro diagnostics by delivering cost-competitive bio-semiconductor solutions that enable early and accurate disease detection.
Our biochips achieve ultra-high sensitivity by detecting biomolecules at extremely low concentrations because the change of electrical discharge distribution on silicon empowers Femtogram/mL precision. To ensure high specificity, we apply advanced biochemical processes, including pharmaceutical-grade bioprobe engineering, production, and surface deposition, so that each biochip is precisely tuned to its intended target. The First Bio-Fabless Diagnostics Company
Molecule-Agnostic Bio-Semiconductor Solutions for Unmet Clinical Needs.
Our semiconductor-based diagnostic platform delivers fast, highly sensitive, and highly specific results across a wide range of biomarkers. By leveraging mature-node semiconductor foundry manufacturing, we design scalable and cost-efficient chips suitable for large-scale clinical deployment.
Novascope Biochips is committed to democratizing in-vitro diagnostics by delivering cost-competitive bio-semiconductor solutions that enable early and accurate disease detection.
Our biochips achieve ultra-high sensitivity by detecting biomolecules at extremely low concentrations because the change of electrical discharge distribution on silicon empowers Femtogram/mL precision. To ensure high specificity, we apply advanced biochemical processes, including pharmaceutical-grade bioprobe engineering, production, and surface deposition, so that each biochip is precisely tuned to its intended target.
Molecule-Agnostic Bio-Semiconductor Solutions for Unmet Clinical Needs.
Our semiconductor-based diagnostic platform delivers fast, highly sensitive, and highly specific results across a wide range of biomarkers. By leveraging mature-node semiconductor foundry manufacturing, we design scalable and cost-efficient chips suitable for large-scale clinical deployment.
One Chip. Multiple Modalities.
Our proprietary analogue ASIC architecture is optimized to minimize signal interference and ensure exceptional sensitivity, while advanced surface biofunctionalization delivers molecular specificity. These capabilities enable Novascope’s molecule-agnostic bio-semiconductor chips to function as complete diagnostic solutions for unmet critical needs in medical diagnostics.
0
+
Min to Result
0
+
Patents Filed
0
+
experience
Semiconductor Sensors, Clinically Proven DiagnosticsFrom Alzheimer’s to Sepsis, From Chips to Clinics
CSO, Board Director
Dr. Chang-Fu Kuo
Prof. of Rheumatology. Former R&D Dir CGMH AI Center. Stanford Top 2% Scientist.
02
Integration of Biochemistry & Semiconductors
Combining biochemistry with semiconductor sensing for accurate and efficient diagnostics.
03
Cost-Effective Early Disease Detection
Enabling affordable early detection to lower healthcare costs and support timely care.
Mission Statement
Pioneering the Next Generation of Diagnostics Platform Built on Semiconductor Sensors
Request Investor Deck : ir@novascopedx.com
Novascope is a semiconductor-driven biotech company developing ultra-sensitive biochips for rapid, early disease detection and precision diagnostics
© 2026 Novascope Diagnostics Inc.